GeneDx (NASDAQ:WGS) CEO Katherine Stueland Sells 2,172 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 2,172 shares of GeneDx stock in a transaction that occurred on Wednesday, April 29th. The stock was sold at an average price of $65.19, for a total transaction of $141,592.68. Following the completion of the transaction, the chief executive officer directly owned 93,216 shares in the company, valued at approximately $6,076,751.04. The trade was a 2.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Katherine Stueland also recently made the following trade(s):

• On Thursday, March 26th, Katherine Stueland sold 46,933 shares of GeneDx stock. The stock was sold at an average price of $63.17, for a total transaction of $2,964,757.61.
• On Monday, March 16th, Katherine Stueland sold 17,179 shares of GeneDx stock. The shares were sold at an average price of $76.80, for a total transaction of $1,319,347.20.
• On Wednesday, March 4th, Katherine Stueland sold 25,459 shares of GeneDx stock. The shares were sold at an average price of $78.61, for a total transaction of $2,001,331.99.

GeneDx Price Performance

Shares of WGS opened at $65.38 on Friday. The company has a market cap of $1.91 billion, a price-to-earnings ratio of -87.17 and a beta of 2.06. GeneDx Holdings Corp. has a twelve month low of $55.17 and a twelve month high of $170.87. The company has a quick ratio of 2.34, a current ratio of 2.46 and a debt-to-equity ratio of 0.16. The company has a 50 day moving average of $71.45 and a two-hundred day moving average of $107.37.

GeneDx (NASDAQ:WGS) last announced its earnings results on Monday, February 23rd. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.03. The company had revenue of $120.99 million during the quarter, compared to the consensus estimate of $120.80 million. GeneDx had a negative net margin of 4.92% and a positive return on equity of 14.73%. As a group, analysts predict that GeneDx Holdings Corp. will post 0.75 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have weighed in on WGS. Piper Sandler restated an “overweight” rating and issued a $130.00 target price (down from $160.00) on shares of GeneDx in a research note on Tuesday, February 24th. BTIG Research lowered their target price on shares of GeneDx from $200.00 to $170.00 and set a “buy” rating for the company in a research note on Tuesday, February 24th. Wall Street Zen downgraded shares of GeneDx from a “buy” rating to a “hold” rating in a research note on Sunday, February 8th. Jefferies Financial Group set a $150.00 target price on shares of GeneDx in a research report on Monday, February 23rd. Finally, Zacks Research downgraded shares of GeneDx from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 24th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $134.17.

Institutional Trading of GeneDx

Several large investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. grew its position in GeneDx by 4.5% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,220,502 shares of the company’s stock worth $158,738,000 after purchasing an additional 52,322 shares during the last quarter. Vanguard Group Inc. grew its position in GeneDx by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 1,189,069 shares of the company’s stock worth $154,650,000 after purchasing an additional 18,647 shares during the last quarter. Franklin Resources Inc. grew its position in GeneDx by 60.4% during the 4th quarter. Franklin Resources Inc. now owns 1,092,988 shares of the company’s stock worth $142,154,000 after purchasing an additional 411,607 shares during the last quarter. Westfield Capital Management Co. LP grew its position in GeneDx by 87.1% during the 4th quarter. Westfield Capital Management Co. LP now owns 1,018,261 shares of the company’s stock worth $132,435,000 after purchasing an additional 474,167 shares during the last quarter. Finally, Invesco Ltd. grew its position in GeneDx by 59.2% during the 4th quarter. Invesco Ltd. now owns 786,466 shares of the company’s stock worth $102,288,000 after purchasing an additional 292,394 shares during the last quarter. Hedge funds and other institutional investors own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.